An interventional study of Transcraneal Magnetic Stimulation (rTMS) in Stroke Sequelae, Chronic Pain and Fibromyalgia, sponsored by Hospital Donostia. Completed at 2 sites in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Hospital Donostia · Not applicable, Interventional, and Treatment
Background: Chronic non-nociceptive or nociplastic pain and neurological sequelae following stroke are associated with substantial functional impairment and reduced quality of life. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique capable of modulating cortical excitability and functional brain networks involved in pain processing and neurological recovery. However, its clinical response may vary according to the underlying phenotype and therapeutic target.
Objective: To evaluate the safety, tolerability, and clinical response to rTMS as a complementary therapeutic intervention in patients with chronic non-nociceptive pain, fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Long COVID, and post-stroke sequelae, and to explore differences in treatment response across clinical conditions.
Methods: A clinical study including baseline assessment, rTMS intervention, post-treatment evaluation, and follow-up was conducted. The protocol consisted of ten treatment sessions administered over two consecutive weeks. For chronic pain, fibromyalgia, ME/CFS, and Long COVID, excitatory stimulation at 10 Hz was delivered over the left primary motor cortex (M1), with 1,000 pulses per session. For post-stroke sequelae, inhibitory stimulation at 1 Hz with 600 pulses was applied according to the predominant clinical deficit. Target localization was performed using neuronavigation when individual magnetic resonance imaging was available and the international 10-20 system when it was not. Clinical outcomes included pain, fatigue, sleep, quality of life, motor function, and language performance, assessed using validated clinical scales.
2. FUNDAMENTALS OF TMS/rTMS
Transcranial magnetic stimulation (TMS) is a non-invasive neuromodulation technique that uses a time-varying magnetic field to induce electrical currents in the brain. Repetitive TMS (rTMS) delivers trains of pulses capable of producing lasting neurophysiological effects beyond the stimulation period. The magnitude and direction of these effects depend on the cortical target, stimulation frequency and intensity, number of pulses and sessions, and the neurophysiological state of the participant.
Low-frequency protocols (e.g., 1 Hz) are generally associated with reduced cortical excitability, whereas higher frequencies may increase excitability. However, responses vary substantially among individuals and should not be considered universal.
The effects of rTMS have been linked to synaptic plasticity mechanisms resembling long-term potentiation (LTP) and long-term depression (LTD), as well as changes in functional connectivity. These mechanisms provide the biological rationale for its use as an adjunct to rehabilitation.
2.1 Post-Stroke Applications
In stroke rehabilitation, rTMS is primarily used to modulate the balance of cortical excitability between hemispheres. Inhibitory stimulation may be applied to the contralesional hemisphere, whereas excitatory stimulation may target the affected hemisphere. Potential benefits have been reported for motor recovery, spasticity, and language rehabilitation when combined with conventional therapy.
2.2 Chronic Pain and Fibromyalgia
Motor cortex stimulation has been investigated as a treatment for chronic pain conditions. Proposed mechanisms involve modulation of thalamocortical and sensorimotor networks involved in pain processing. Meta-analyses suggest that rTMS may reduce pain in selected conditions, although clinical responses remain variable.
2.3 ME/CFS and Long COVID
Evidence supporting rTMS in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID remains limited. Interest in neuromodulation stems from reported abnormalities in cortical excitability, network connectivity, cognition, and fatigue. Its use should therefore be regarded as investigational and complementary.
3. STUDY RATIONALE
Stroke, fibromyalgia, chronic pain disorders, ME/CFS, and Long COVID significantly affect functional capacity, independence, and quality of life. Many individuals continue to experience disabling symptoms despite standard treatments. Neuromodulation may represent a useful complementary therapeutic strategy.
The central hypothesis is that an individualized and standardized rTMS protocol will demonstrate a favorable safety profile and produce clinically meaningful improvements, although treatment responses may differ across diagnostic groups due to distinct pathophysiological mechanisms.
4. HYPOTHESES rTMS administered using a standardized and individualized protocol will be safe and well tolerated.
Treatment will be associated with favorable changes in pain, fatigue, functionality, and quality of life.
Standardized procedures for target localization and intensity determination will reduce inter-session variability.
The magnitude and pattern of clinical response will differ among diagnostic groups.
5. OBJECTIVES 5.1 General Objective
To evaluate the safety, tolerability, and clinical effects of rTMS as a complementary therapeutic intervention in patients with fibromyalgia, ME/CFS, post-stroke sequelae, and Long COVID.
5.2 Specific Objectives Assess safety and tolerability through systematic recording of adverse events. Evaluate clinical outcomes using validated scales before and after treatment and during follow-up.
Analyze changes in pain, fatigue, functionality, and quality of life. Apply standardized procedures for target localization and coil positioning. Determine individual motor thresholds and use them to guide stimulation intensity when appropriate.
Explore relationships between TMS-EMG measures and clinical outcomes. Compare response patterns across clinical subgroups. 6. MATERIALS AND METHODS 6.1 Study Design
This clinical study includes baseline assessment, rTMS intervention, post-treatment evaluation, and follow-up. The protocol consists of ten treatment sessions administered over two consecutive weeks. Outcomes are assessed immediately after treatment and approximately one month later.
6.2 Participants
Adults aged 18-75 years who meet diagnostic criteria for the study conditions will be eligible. Approximately 46 participants per condition are expected to provide preliminary information regarding feasibility, adherence, attrition, and potential efficacy signals.
6.3 Baseline Assessment
Baseline evaluations include demographic and clinical data, medical history, medication review, physical examination, and condition-specific outcome measures. Instruments may assess motor function, cognition, spasticity, pain, fatigue, sleep quality, and quality of life.
6.4 Target Localization
When individual MRI data are available, neuronavigation will be used to improve target accuracy and reproducibility. In the absence of MRI, stimulation targets will be identified using the International 10-20 EEG system. Target selection will be based on clinical indication and available evidence.
6.5 TMS-EMG and Motor Threshold Assessment
Combining TMS with electromyography (EMG) allows recording of motor evoked potentials (MEPs) and assessment of corticospinal excitability. Resting motor threshold (RMT) will be used to individualize stimulation intensity. Neurophysiological findings will be interpreted together with clinical outcomes.
6.6 Stimulation Protocols
For fibromyalgia, ME/CFS, Long COVID, and nociplastic pain conditions, the protocol uses excitatory 10-Hz stimulation over the left primary motor cortex. For post-stroke participants, inhibitory 1-Hz stimulation may be applied to cortical regions selected according to the predominant clinical deficit. These parameters are protocol-specific and not intended as universal recommendations.
7. SAFETY MONITORING
rTMS generally demonstrates a favorable safety profile when administered according to established guidelines. Common adverse effects include headache, scalp discomfort, neck pain, dizziness, and transient fatigue. Seizure is a rare but serious adverse event requiring careful risk assessment. Screening procedures include evaluation of metallic implants, electronic devices, and other contraindications. Adverse events will be systematically recorded and classified according to severity and relationship to treatment.
8. OUTCOME EVALUATION
The primary safety outcome is the frequency and severity of adverse events. Clinical outcomes include pain, fatigue, sleep quality, quality of life, motor function, cognition, and disability measures. Particular attention will be paid to the clinical relevance of observed changes and to the relationship between neurophysiological and functional outcomes.
9. ETHICAL CONSIDERATIONS AND DATA MANAGEMENT
Written informed consent will be obtained before any study procedures. Participants will be identified using coded records, and all personal information will remain confidential. The study will comply with the Declaration of Helsinki, Good Clinical Practice guidelines, and applicable data protection regulations, including GDPR requirements. Participants may withdraw from the study at any time without penalty.
2,998 studies on the registry are indexed under Chronic Pain; 706 are open to participants now.
This study's enrollment of 47 is below the median of 60 across 2,209 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →Hospital Donostia is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of ME will be made according to 2016 Fibromyalgia diagnostic criteria (see Supplementary Appendix B, Supplemental Digital Content
1, https://links.lww.com/PHM/B78 ).
Exclusion Criteria:
Active and control group . Active group received treatment. Control group did not received treatment
TMS
Device: Transcraneal Magnetic Stimulation (rTMS)
Applied transcraneal magnetic stimulation
Number of adverse effects
Safety and adverse effects
Time frame: 1 year
Visual Analogue Scale (VAS)
Validated self-report measure consisting of a 10-cm line ranging from 0 ("no pain") to 10 ("worst imaginable pain"). Participants indicated their perceived pain intensity by marking a point along the scale, with higher scores reflecting greater pain severity.
Time frame: 1 year
Fatigue Assessment Scale (FAS)
A validated 10-item self-report questionnaire that measures both physical and mental fatigue. Each item is scored on a 5-point Likert scale, resulting in a total score ranging from 10 to 50, with higher scores indicating greater fatigue severity.
Time frame: 1 year
Fibromyalgia Impact Questionnaire (FIQ)
A validated disease-specific instrument that evaluates physical functioning, work-related difficulties, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. Total scores range from 0 to 100, with higher scores indicating a greater impact of fibromyalgia and increased functional impairment.
Time frame: 1 year
Fugl-Meyer Assessment (FMA)
A validated stroke-specific scale that evaluates motor function, sensory function, balance, joint range of motion, and joint pain. Higher scores indicate better sensorimotor performance and lower levels of neurological impairment.
Time frame: 1 year
Boston Diagnostic Aphasia Examination (BDAE)
A standardized neuropsychological battery designed to evaluate aphasia severity and language performance across multiple domains, including spontaneous speech, auditory comprehension, repetition, reading, and writing. Higher scores indicate better language function and fewer aphasic impairments
Time frame: 1 year
Communicative Effectiveness Index (CETI)
A validated caregiver-rated measure of communication ability in everyday situations. The questionnaire evaluates the effectiveness of verbal communication across a variety of functional contexts, with higher scores indicating better communicative performance and greater independence in daily interactions.
Time frame: 1 year
Epworth Sleepiness Scale (ESS)
A validated 8-item self-report questionnaire that evaluates the likelihood of falling asleep in a variety of everyday situations. Total scores range from 0 to 24, with higher scores indicating greater levels of excessive daytime sleepiness.
Time frame: 1 year
Short Form-36 Health Survey (SF-36)
A validated 36-item questionnaire that evaluates eight domains of physical and mental health, including physical functioning, bodily pain, vitality, social functioning, and emotional well-being. Scores range from 0 to 100, with higher scores indicating better health-related quality of life.
Time frame: 1 year
Documents are hosted by the registry — open the source record to download them.
Plan to share: No — I don t have detailes personalized data
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Donostia